RPG Life Sciences Limited — Earnings Release 2022

Oct 29, 2021

==> picture [506 x 98] intentionally omitted <==

October 29, 2021

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sir/Madam,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2021.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary

==> picture [68 x 73] intentionally omitted <==

Encl.: as above

==> picture [531 x 56] intentionally omitted <==

==> picture [81 x 40] intentionally omitted <==

Q2 FY22 Revenue from operations grew by 16% Y‐o‐Y and 4% Q‐o‐Q PBT grew by 52% Y‐o‐Y and 16% Q‐o‐Q.

Mumbai, 29 October, 2021 : RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2021.

Q2 FY22 Highlights	Y‐o‐Y Revenue from operations	Y‐o‐Y PBT
	Rs 112.65 crores – up from Rs 97.13 crores	Rs 22.35 crores – up from Rs 14.73 crores
H1 FY22 Highlights	Rs 220.78 crores – up from Rs 188.78 crores	Rs 41.62 crores – up from Rs 27.56 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 52% Y‐o‐Y and by 16% Q‐o‐Q for Q2 FY22, maintaining the upward trajectory in EBITDA margins, which improved from 19.7% to 23.5% Y‐o‐Y. Revenue from operations at Rs 112.65 crores registered a growth of 16% Y‐o‐Y and a growth of 4% Q‐o‐Q for Q2 FY22. For H1 FY22 too, the company recorded EBITDA margin expansion from 19.3% to 22.6% Y‐o‐Y.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “I am pleased to share that in Q2 FY22, we continued to deliver a robust performance. Revenue and PBT grew by 16% and 52% respectively Y‐o‐Y. EBITDA margins’ record‐setting trajectory continued, growing from 19.7% to 23.5% Y‐o‐Y. The Company continues to remain debt free with highest‐ever net cashflow generated from operations in H1 FY22.

All the three business segments have reflected consistent growth in revenues driven by both new and existing products and significant PBT Margin expansion driven by efficient Opex control measures and good product mix. Domestic Formulations recorded growth better than the market with healthy volume growth. Our new portfolio is witnessing an impressive uptake and we are strongly foraying into Rheumatology, which is further strengthening our endeavour of expanding into Specialty Segment. In the International Formulations business, our growth was somewhat subdued due to the political unrest in one of our key markets, Myanmar. However, rest of the International business reflected strong performance. API business also recorded robust growth. Going forward, maintaining the growth momentum in both top‐line and bottom‐line across the business segments by implementing all the initiatives as per our transformation agenda will continue to remain our key priority.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research‐based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation‐led technology businesses.

Media Contact:

Sumeet Chatterjee Senior Vice President – Corporate Brand and Group Communications +91 9820340650 | sumeet@rpg.in

==> picture [134 x 27] intentionally omitted <==